Intracellular lipid accumulation and shift during diabetes progression;Ektope Fettspeicherung bei Insulinresistenz und Diabetes Mellitus Typ 2

Wiener Medizinische Wochenschrift

Volumn 164, Issue 15-16, 2014, Pages 320-329

  Wolf, Peter ^a   Winhofer, Yvonne ^a   Anderwald, Christian Heinz ^a,b,c,d   Krššák, Martin ^a   Krebs, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CNR   (Italy)

^c Mariahilf Community Pharmacy   (Austria)

^d Specialized Hospital Complex Agathenhof   (Austria)

Author keywords

Diabetic cardiomyopathy; Ectopic lipid deposition; Glucose tolerance; Insulin resistance; Intramyocellular lipid content; NAFLD; Type 2 diabetes mellitus

Indexed keywords

FATTY ACID; GLUCOSE BLOOD LEVEL;

BLOOD; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FUNCTION; HUMAN; INSULIN RESISTANCE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD GLUCOSE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84930725042     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-014-0292-y     Document Type: Review

References (113)

1. Rieder A, Rathmanner T, Kiefer I, Dorner T, Kunze M. Österreichischer Diabetesbericht 2004 – Daten, Fakten, Strategien. 2004. http://www.oedg.org/pdf/Diabetesbericht_I.pdf.
2. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.
4. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171–6.
5. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473–81.
6. Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care. 2009;32(Suppl. 2):S164–7.
7. Birkenfeld AL, Shulman GI. Non alcoholic fatty liver disease, hepatic insulin resistance and type 2 diabetes. Hepatology. 2014;59(2):713–23.
8. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375(9733):2267–77.
9. Mcgavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170–5.
10. Krššák M, Winhofer Y, Göbl C, Bischof M, Reiter G, Kautzky-Willer A, et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia. 2011;54(7):1871–8.
11. Rijzewijk L, van der Meer R, Smit J, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52(22):1793–9.
12. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785–9.
13. Randle PJ, Garland PB, Newsholmei EA, Hales CN. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci. 1965;131(1):324–33.
14. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37(8):1020–4.
15. Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997;46(6):1001–9.
16. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid—induced insulin resistance in humans. J Clin Invest. 1996;97(12):2859–65.
17. Pan D, Lillioja S, Kriketos D, Milner M, Baur L, Bogardus C, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983–8.
18. Forouhi NG, Jenkinson G, Thomas EL, Mullick S, Mierisova S, Bhonsle U, et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia. 1999;42:932–5.
19. Krssak M, Petersen KF, Dresner A, Dipietro L, Vogel SM, Rothman DL, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1 H NMR spectroscopy study. Diabetologia. 1999;42:113–6.
20. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350(7):664–71.
21. Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med. 2005;2(9):e233.
22. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007;104(31):12587–94.
23. Szendroedi J, Kaul K, Kloock L, Straßburger K, Schmid A, Chmelik M, et al. Lower fasting muscle mitochondrial activity relates to hepatic steatosis in humans. Diabetes Care. 2014;37(2):468–74.
24. Hwang J-H, Stein DT, Barzilai N, Cui M-H, Tonelli J, Kishore P, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab. 2007;293(6):E1663–9.
25. Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes. 2002;51(10):3025–32.
26. Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Man CD, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes. 2004;53:3048–56.
27. Williams KH, Shackel NA, Gorrell MD, Mclennan SV, Twigg SM, et al. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34(1):84–129.
28. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in europe. N Engl J Med. 2008;359:2105–20.
29. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555–63.
30. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430–5.
31. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1285–6.
32. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16.
33. Lingvay I, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B, et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab. 2009;94(10):4070–6.
34. Heni M, Staiger H, Schwenzer NF, Peter A, Schick F, Claussen CD, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev. 2010;26(3):200–5.
35. Tushuizen M, Bunck M, Pouwels P, Bontemps S, Van Waesberghe J, Schindhelm R, et al. Pancreatic fat content and b-cell function in men with and without type 2 diabetes. Diabetes Care. 2007;30(11):2916–21.
36. Bertoni A, Tsai A, Kasper E, Brancati F. Diabetes and idiopathic cardiomyopathy. Diabets Care. 2003;26(10):2791–5.
37. Bell DSH. Diabetic cardiomyopathy. Diabetes Care. 2003;26(10):2949–51.
38. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D’Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49(3):417–23.
39. Iozzo P, Lautamaki R, Borra R, Lehto H-R, Bucci M, Viljanen A, et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab. 2009;94(11):4472–82.
40. Hammer S, van der Meer RW, Lamb HJ, Schär M, de Roos A, Smit JWA, et al. Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab. 2008;93(2):497–503.
41. Hammer S, Van Der Meer RW, Lamb HJ, De Boer HH, Bax JJ, De Roos A, et al. Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2008;295:714–8.
42. Winhofer Y, Krssák M, Jankovic D, Anderwald C-H, Reiter G, Hofer A, et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes. 2012;61(5):1210–6.
43. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012;35(2):389–95.
44. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47(1):51–8.
45. Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59(2):461–70.
46. Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol. 2010;56(3):225–33.
47. Lautamäki R, Borra R, Iozzo P, Komu M, Lehtima T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;291:282–90.
48. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Med. 1994;12(3):487–95.
49. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276(5):E977–89.
50. Reingold J, McGavock J, Kaka S, Tillery T, Victor R, Szczepaniak L. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab. 2005;289:E935–9.
51. Krssak M, Hofer H, Wrba F, Meyerspeer M, Brehm A, Steindl P, et al. Liver fat content and insulin resistance in chronic hepatitis C patients. Eur J Radiol. 2010;74(3):e60–6.
52. Longo R, Ricci C, Masutti F, Vidimari R, Croce L, Vercich L, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol. 1993;28(4):297–302.
53. Dixon W. Simple proton spectroscopic imaging. Radiology. 1984;153(1):189-94.
54. Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med. 1997;37(4):484–93.
55. Dimitrov I, Ren J, Douglas D, Sherry A, Malloy C. In vivo detection of trans-fatty acids by 13C MRS at 7T. Proc Intl Soc Mag Reson Med. 2010;374.
56. Gajdosik M, Chmelik M, Just-Kukurova I, Bogner W, Valkovic L, Trattnig S, et al. In vivo relaxation behavior of liver compounds at 7 tesla, measured by single-voxel proton MR spectroscopy. J Magn Reson Imaging. In press 2013.
57. Hwang J, Bluml S, Leaf A, Ross B. In vivo characterization of fatty acids in human adipose tissue using natural abundance 1H decoupled 13C MRS at 1.5 T: clinical applications to dietary therapy. NMR Biomed. 2003;16:160–7.
58. Johnson N, Walton D, Sachinwalla T, Thompson C, Smith K, Ruell P, et al. Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology. 2008;47:1513–23.
59. Ren J, Dimitrov I, Sherry A, Malloy C. Composition of adipose tissue and marrow fat in humans by 1H NMR at 7 Tesla. J Lipid Res. 2008;49:2055–62.
60. Valkovic L, Gajdosik M, Traussnigg S, Wolf P, Chmelik M, Bogner W, et al. Assessment of hepatic metabolism by fast and localiced 31P MRS saturation transfer at 7T: reproducibiltiy and first clinical application in patients with non alcoholic fatty liver disease. Eur Radiol. 2014;24(7):1602–9.
61. Petersen K, Shulman G. Etiology of insulin resistance. Am J Med. 2006;119(5):10–6.
62. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and ikB-alpha. Diabetes. 2002;51:2005–11.
63. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277(52):50230–6.
64. Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin. Ann N Y Acad Sci. 2002;967:146–57.
65. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852–71.
66. Cortright RN, Azevedo JL, Zhou Q, Sinha M, Pories WJ, Itani SI, et al. Protein kinase C modulates insulin action in human skeletal muscle. Am J Physiol Endocrinol Metab. 2000;278(3):E553–62.
67. Bollag GE, Roth RA, Beaudoin J, Mochly-Rosen D, Koshland DE. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci U S A. 1986;83(16):5822–4.
68. Nowotny B, Zahiragic L, Krog D, Nowotny PJ, Herder C, Carstensen M, et al. Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans. Diabetes. 2013;62:2240–8.
69. Magkos F, Su X, Bradley D, Fabbrini E, Conte C, Eagon JC, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology. 2012;142(7):1444.e2–6.e2.
70. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011;108(39):16381–5.
71. Samuel VT, Liu Z-X, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345–53.
72. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, Jiang DC. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci U S A. 2011;108(14):5748–52.
73. Zhang L, Ussher JR, Oka T, Cadete VJJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res. 2011;89(1):148–56.
74. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, et al. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem. 2009;284(52):36312–23.
75. Amati F. Revisiting the diacylglycerol-induced insulin resistance hypothesis. Obes Rev. 2012;13(21):40–50.
76. Brown JM, Betters JL, Lord C, Ma Y, Han X, Yang K, et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J Lipid Res. 2010;51(11):3306–15.
77. Timmers S, Nabben M, Bosma M, van Bree B, Lenaers E, van Beurden D, et al. Augmenting muscle diacylglycerol and triacylglycerol content by blocking fatty acid oxidation does not impede insulin sensitivity. Proc Natl Acad Sci U S A. 2012;109(29):11711–6.
78. Cantley JL, Yoshimura T, Camporez JPG, Zhang D, Jornayvaz FR, Kumashiro N, et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc Natl Acad Sci U S A. 2013;110(5):1869–74.
79. Rando R, Young N. The stereospecific activation of protein kinase C. Biochem Biophys Res. 1984;122(2):818–23.
80. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312(5774):734–7.
81. Huijsman E, Van De Par C, Economou C, Van Der Poel C, Lynch GS, Schoiswohl G, et al. Adipose triacylglycerol lipase deletion alters whole body energy metabolism and impairs exercise performance in mice. Am J Clin Nutr. 2009;297:505–13.
82. Sitnick MT, Basantani MK, Cai L, Schoiswohl G, Yazbeck CF, Distefano G, et al. Skeletal muscle triacylglycerol hydrolysis does not influence metabolic complications of obesity. Diabetes. 2013;62(10):3350–61.
83. Tuunanen H, Engblom E, Naum A, Någren K, Hesse B, Airaksinen KEJ, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114(20):2130–7.
84. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2005;90(6):3191–6.
85. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603–8.
86. Petersen KF, Dufour S, Morino K, Yoo PS, Cline GW, Shulman GI. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. Proc Natl Acad Sci U S A. 2012;109(21):8236–40.
87. Rabøl R, Petersen KF, Dufour S, Flannery C, Shulman GI. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A. 2011;108(33):13705–9.
88. Van der Meer RW, Hammer S, Lamb HJ, Frölich M, Diamant M, Rijzewijk LJ, et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab. 2008;93(7):2702–8.
89. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005;72205:930–4.
90. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 2000;49:827–31.
91. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364–70.
92. Ravikumar B, Gerrard J, Man CD, Firbank MJ, Lane A, English PT, et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes. 2008;57:2288–95.
93. Van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119(15):2069–77.
94. Jankovic D, Winhofer Y, Promintzer-Schifferl M, Wohlschläger E, Anderwald CH, Wolf P, et al. Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus. PLoS One. 2012;7(12):1–7.
95. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin and metformin combination on hepatic steatosis in type 2 diabetes: treatment of hepatic steatosis in diabetes. J Diabetes Complications. 2008;21(3):137–42.
96. Thamer C, Machann J, Bachmann O, Haap M, Dahl D, Wietek B, et al. Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab. 2003;88(4):1785–91.
97. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab. 2001;86(12):5755–61.
98. Bergman BC, Hunerdosse DM, Kerege A, Playdon MC, Perreault L. Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans. Diabetologia. 2012;55(4):1140–50.
99. Szendroedi J, Schmid AI, Chmelik M, Toth C, Brehm A, Krssak M, et al. Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med. 2007;4(5):e154.
100. Schmid AI, Szendroedi J, Chmelik M, Krssák M, Moser E, Roden M. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care. 2011;34(2):448–53.
101. Szendroedi J, Chmelik M, Schmid AI, Nowotny P, Brehm A, Krssak M, et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology. 2009;50(4):1079–86.
102. Franko A, von Kleist-Retzow J-C, Neschen S, Wu M, Schommers P, Böse M, et al. Liver adapts mitochondrial function to insulin resistant and diabetic states in mice. J Hepatol. 2014;60(4):816–23.
103. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14(6):804–10.
104. Johnson NA, Walton DW, Sachinwalla T, Thompson CH, Smith K, Ruell PA, et al. Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology. 2008;47(5):1513–23.
105. De Wit NJW, Afman LA, Mensink M, Müller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol. 2012;57:1370–3.
106. Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008;48(2):300–7.
107. De Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol. 2012;303(5):G589–99.
108. Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012;95:1003–12.
109. Rosqvist F, Iggman D, Kullberg J, Jonathan Cedernaes J, Johansson H-E, Larsson A, et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014;63(7):2356–68.
110. Jans A, Konings E, Goossens GH, Bouwman FG, Moors CC, Boekschoten MV, et al. PUFAs acutely affect triacylglycerol-derived skeletal muscle fatty acid uptake and increase postprandial insulin sensitivity. Am J Clin Nutr. 2012;95:825–36.
111. Russo SB, Baicu CF, Van Laer A, Geng T, Kasiganesan H, Zile MR, et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest. 2012;122(11):3919–30.
112. Duda MK, O’Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33–41.
113. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, et al. Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med. 2013;368(14):1279–90.